Latest News Archive
Please select Category, Year, and then Month to display items
14 June 2024
|
Story Anthony Mthembu
|
Photo Suplied
Jeremiah Hlahla, a UFS student completing his PhD in Botany at the University of Debrecen as part of an exchange initiative funded by the Erasmus+ Mobility Programme.
As part of an exchange initiative facilitated by the Erasmus+ Mobility Programme, Jeremiah Hlahla, a student at the University of the Free State (UFS), is nearing the completion of his PhD studies at the University of Debrecen in Hungary. Hlahla’s journey, which began in February 2024 and is set to conclude in July 2024, has been a remarkable learning opportunity. “As a first time-traveller to Europe, I have thoroughly enjoyed engaging with people from different countries and cultures,” he said.
The benefits of international collaboration
Hlahla is currently pursuing a PhD in Botany, focusing on plant stress physiology. “My current PhD project investigates the physiological, biochemical and morphological responses of vegetable-type soybean, or edamame, to combined drought and heat stress,’’ he explained. He considers the University of Debrecen the ideal institution to complete his research due to its extensive expertise and resources in similar projects. He noted that his colleagues at Debrecen conduct significant work on plant protection against biotic and abiotic stresses, including salt and drought stress, as well as proteins and amino acids in barley and other legumes.
Given the vast knowledge available on similar projects, Hlahla has found substantial engagement with his work at the University of Debrecen. “Upon arrival, I delivered an introductory lecture presenting my UFS project on the synergistic effects of combined drought and heat stress on the physiology and biochemistry of edamame. It was an engaging session as everyone could relate to my work and asked many questions,’’ he said.
Insights gained from the exchange
Hlahla has also gained valuable lessons that will assist him in his research career, including biotechnology and physiology tools. “I learned how to prepare samples and use high-performance liquid chromatography (HPLC) and reversed-phase ultra-high-performance liquid chromatography (UHPLC) to quantify proteins and amino acids,’’ he said. These techniques are beneficial not only for his current work but will also support future soybean research.
As his experience at the University of Debrecen nears its end, Hlahla reflects on the collaborations and friendships he has formed, which stand out as a significant highlight.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004